Glenmark Pharmaceuticals Limited — Updates, 10-02-2025: Press Release

Glenmark Pharmaceuticals has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi®, a novel topical treatment for acne vulgaris in patients aged 12 and older. This marks a significant advancement in dermatological care, as Winlevi® is the first topical treatment with a unique mechanism of action in nearly four decades, utilizing clascoterone, a topical androgen receptor inhibitor. Clinical studies have demonstrated its effectiveness in reducing both inflammatory and non-inflammatory acne lesions, with a favorable safety profile.

Glenmark's collaboration with Cosmo Pharmaceuticals, initiated in September 2023, positions the company to enhance its dermatology portfolio and address the substantial global market for acne treatments, impacting the quality of life for millions. CEO Christoph Stoller emphasized Glenmark's commitment to delivering innovative solutions that improve dermatology care. This approval highlights potential growth opportunities for Glenmark and strengthens its competitive standing in the healthcare market.